Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC
Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.
Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with nonsmall cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.
Looking at treatment-naïve patients with ROS1 fusionpositive lung cancers, this trial had more than 50 patients, all of which had a ROS1 fusion detected by either fluorescence in situ hybridization or next-generation sequencing. Topline results in terms of activity showed the objective response rate was high at 77%, Drilon says. The majority of patients had disease regression with this agent and also experienced some deep and durable responses. This is something you hope to see with an active targeted therapeutic, Drilon comments.
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
